Authors determined variables that pose a risk for immune reconstitution syndrome (IRS) and have shown that discontinuation of calcineurin inhibitors was independently associated with 5-fold increased risk of IRS in transplant recipients with cryptococcosis.
Keywords: fungal infections, Cryptococcus, transplant, immunosuppression
Abstract
Background. Risk factors including how changes in immunosuppression influence the occurrence of immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococcosis have not been fully defined.
Methods. SOT recipients with cryptococcosis were identified and followed for 12 months. IRS was defined based on previously proposed criteria.
Results. Of 89 SOT recipients, 13 (14%) developed IRS. Central nervous system (CNS) disease (adjusted odds ratio [AOR], 6.23; P = .03) and discontinuation of calcineurin inhibitor (AOR, 5.11; P = .02) were independently associated with IRS. Only 2.6% (1/13) of the patients without these risk factors developed IRS compared with 18.8% (6/32) with 1 risk factor, and 50% (6/12) with both risk factors (χ2 for trend, P = .0001). Among patients with CNS disease, those with neuroimaging abnormalities (P = .03) were more likely to develop IRS, irrespective of serum or CSF cryptococcal antigen titers and fungemia. Graft rejection after cryptococcosis was observed in 15.4% (2/13) of the patients with IRS compared with 2.6% (2/76) of those without IRS (P = .07).
Conclusions. We determined variables that pose a risk for IRS and have shown that discontinuation of calcineurin inhibitors was independently associated with 5-fold increased risk of IRS in transplant recipients with cryptococcosis.
(See the Editorial Commentary by Fishman on pages 45–7.)
Cryptococcus neoformans is a significant opportunistic pathogen in solid organ transplant (SOT) recipients. An estimated 2.8% and up to 5% of transplant recipients develop cryptococcosis after transplant [1–5]. Central nervous system (CNS) involvement has been documented in 54%–72% of patients with cryptococcal disease. Mortality rates in organ transplant recipients with cryptococcosis range from 15% to 20% [1, 2].
CD4+ T-helper (Th) responses are critical mediators of immunity against Cryptococcus. Whereas cells of Th1 and Th17 [6–11] lineage confer protection, T-regulatory cells and Th2 responses compromise host resistance and facilitate disease progression [9, 11, 12]. Cryptococcus per se has immunosuppressive capabilities and preferentially inhibits proinflammatory responses while inducing Th2 [13]. Reversal of pathogen-mediated immunosuppression with effective antifungal therapy restores inflammatory responses [14].
Iatrogenic immunosuppression in transplant recipients is associated with anti-inflammatory responses that are vital for graft tolerance, whereas reduction of immunosuppression has the potential to promote an inflammatory milieu [10]. In transplant patients with serious opportunistic mycoses such as cryptococcosis, the discontinuation or reduction of immunosuppressive therapy upon diagnosis is a common practice [15]. The cumulative effect of reversal of pathogen-induced immunosuppression, withdrawal or reduction of immunosuppression, and administration of effective antifungal therapy is associated with a shift in the host immune repertoire toward physiologic (but sometimes pathologic) inflammatory responses that can lead to immune reconstitution syndrome (IRS) [16]. Thus, restoration of host immunity, although pivotal for the eradication of this yeast, has the potential to contribute to unwanted inflammation. A growing body of literature shows that any clinical condition associated with a rapid reversal of immunosuppression is permissive to the development of IRS [16–18].
This study was undertaken to better characterize the clinical phenomenon of IRS in transplant recipients with cryptococcosis, with the goal to systematically determine variables associated with the occurrence of IRS, and to assess the clinical outcomes in transplant recipients with Cryptococcus-associated IRS.
PATIENTS AND METHODS
The study population consisted of SOT recipients with cryptococcal disease at the participating centers. Cryptococcosis was defined based on criteria proposed by the European Organization for Research and Treatment in Cancer/Mycoses Study Group [19]. This was an observational study with no specific study interventions and procedures. The management of each case was according to standard of care at the transplant centers. Data collected for this study included demographic characteristics, type of organ transplant, prior transplant, cytomegalovirus infection and disease, rejection 6 months prior to cryptococcosis, renal failure (serum creatinine ≥2 mg/dL at the time of diagnosis), immunosuppressive regimen at the time of diagnosis, characteristics of cryptococcal disease, antifungal therapy, management of immunosuppressive therapy after the diagnosis of cryptococcal disease, and outcomes (graft and patient survival) 12 months after the diagnosis.
Patients were considered to have CNS cryptococcosis if they had a positive cerebrospinal fluid (CSF) culture or positive CSF cryptococcal antigen [1, 20]. Involvement of 2 or more noncontiguous organ sites or of the CNS was regarded as disseminated cryptococcal disease. IRS was defined based on case definitions proposed by Singh and Perfect [16] and previously used in the transplant setting [21] (Table 1). Institutional review board approval for this observational study was obtained per local requirements.
Table 1.
Criteria for Immune Reconstitution Syndrome
|
| AND |
|
| AND |
|
Abbreviations: CNS, central nervous system; CT, computed tomography; MRI, magnetic resonance imaging.
Statistical Analysis
Stata/SE software, version 13.1 (StataCorp, College Station, Texas), was used for all statistical comparisons. Logistic regression models were used to evaluate risk factors for IRS. The dependent variable was the binary: IRS/not IRS. The odds ratios (ORs) with 95% confidence intervals (CIs) were determined for each risk factor. A multivariate model was constructed from factors found to be associated with IRS at the 0.10 level in the univariate models. A χ2 test for trend was used to calculate the odds of IRS associated with the number of risk factor present, by comparing the odds of developing IRS with 1 or more risk factors compared with no risk factors. A similar analysis, limited to patients with CNS disease, was employed. The dependent variable was IRS, and ORs with 95% CIs were estimated for each risk factor. The presence of 1 or more statistically significant risk factors were compared to the odds associated with no risk factors in the χ2 for trend test.
RESULTS
Eighty-nine SOT recipients with cryptococcosis were studied, including 35 (39%) kidney, 24 (27%) liver, 12 (13%) heart, 9 (10%) kidney-pancreas, 7 (8%) lung, and 2 (2%) pancreas transplant recipients. None of the patients had human immunodeficiency virus infection. The immunosuppressive regimen was calcineurin inhibitor–based in 83 (93%) of patients, including tacrolimus in 78 and cyclosporine in 5 patients. At the time of diagnosis, 82% of cases were receiving prednisone (median dose, 5 mg) and 34% (30/89) had baseline renal dysfunction
Cryptococcosis developed a median of 17 months (interquartile range [IQR], 6.3–45.4 months) after transplant; 41% of cases occurred within 1 year of transplant. Overall, 65% (58/89) of patients had pulmonary disease with cryptococcosis limited to the lungs in 39.3% (35/89). CNS disease was observed in 46.1% (41/89) and cutaneous disease in 12.4% (11/89) of patients. Disseminated cryptococcosis was observed in 57.3% (51/89), and 36.8% (25/68) grew Cryptococcus from blood cultures. Serum cryptococcal antigen was positive in 82.5% (66/80), with titers ≥1:64 in 62% of patients.
Characteristics of Patients With IRS
Thirteen (14.6%) of 89 transplant recipients with cryptococcosis developed IRS; these included 3 liver (including 1 liver-kidney), 4 kidney, 3 pancreas, and 2 heart transplant recipients. Detailed information of the patients with IRS is outlined in Table 2. IRS developed a median of 45 days (IQR, 15–76 days) after initiation of antifungal therapy
Table 2.
Demographics and Clinical Characteristics of Transplant Recipients With and Without Cryptococcus-Associated Immune Reconstitution Syndrome
| Factor | IRS (n = 13) | No IRS (n = 76) | Odds of IRS, OR (95% CI) | Comparison Group | P Value |
|---|---|---|---|---|---|
| Demographic data | |||||
| Age, y, median (IQR) | 57 (48–60) | 59 (49–65) | 0.98 (.93–1.03) | Continuous | .434 |
| Sex, female | 38.5% (5/13) | 34.2% (26/76) | 1.20 (.36–4.05) | Male | .766 |
| Transplant | |||||
| Kidney | 31% (4/13) | 41% (31/76) | 0.65 (.18–2.238) | Not kidney | .497 |
| Liver/liver-kidney | 31% (4/13) | 26% (20/76) | 1.24 (.34–4.49) | Not liver | .738 |
| Lung | 0/13 | 9% (7/76) | 0.0 (0–3.12) | Not lung | .257 |
| Heart | 15% (2/13) | 13% (10/756) | 1.2 (.23–6.22) | Not heart | .829 |
| Kidney-pancreas/pancreas | 23% (3/13) | 11% (8/76) | 2.55 (.58–11.24) | Not pancreas | .216 |
| Other clinical data | |||||
| Retransplant recipient | 23.% (3/13) | 11% (8/76) | 2.55 (.58–11.24) | Not retransplant | .216 |
| CMV infection | 15.4% (2/13) | 15.8% (12/76) | 0.97 (.19–4.94) | No CMV infection | .970 |
| CMV disease | 7.7% (1/13) | 6.6% (5/76) | 1.18 (.13–11.03) | No CMV disease | .883 |
| Renal failurea | 30.8% (4/13) | 34% (24/76) | 0.85 (.24–3.04) | No renal failure | .808 |
| Prior rejection | 23% (3/13) | 16% (12/76) | 1.6 (.38–6.68) | No rejection | .519 |
| Characteristics of cryptococcal disease | |||||
| Timing of onset posttransplant, mo, median (IQR) | 10.6 (6.8–20.3) | 20.9 (6.0–46.5) | 0.98 (.96–1.01) | Continuous | .245 |
| Serum cryptococcal antigen titer, median (IQR) | 1:128 (1:32–1:512) | 1:64 (1:1–512) | 1.00 (1.00–1.00) | Continuous | .327 |
| Pulmonary disease only | 7.7% (1/13) | 45% (34/76) | 0.10 (.01–.83) | Extrapulmonary | .033 |
| CNS disease | 85% (11/13) | 40% (30/76) | 8.43 (1.74–40.75) | No CNS | .008 |
| Fungemia | 38.5% (5/13) | 36% (20/55) | 1.09 (.31–3.80) | No fungemia | .888 |
| Disseminated disease | 92.3% (12/13) | 51.3% (39/76) | 11.38 (1.41–91.95) | Local disease | .022 |
| Cutaneous disease | 15.4% (2/13) | 12% (9/76) | 1.35 (.26–7.11) | No cutaneous disease | .734 |
| Treatment with AmBd | 25.0% (3/12) | 18% (8/44) | 1.50 (.21–8.04) | Lipid AmB formulations | .598 |
| Treatment with AmBd + 5-FC | 25% (2/8) | 9.1% (2/22) | 3.33 (.38–28.96) | Lipid AmB + 5-FC | .257 |
Data are presented as % (No.) unless otherwise specified.
Abbreviations: 5-FC, 5-flucytosine; AmB, amphotericin B; AmBd, amphotericin B deoxycholate; CI, confidence interval; CMV, cytomegalovirus; CNS, central nervous system; IQR, interquartile range; IRS, immune reconstitution syndrome; OR, odds ratio.
a Creatinine level ≥2 mg/dL at baseline.
Risk Factors for IRS
Demographics and clinical characteristics of cases with and without IRS are shown in Table 2. Age, sex, type of transplant, renal failure at baseline, prior rejection, time to onset of cryptococcosis, fungemia, and serum cryptococcal antigen titer did not correlate with IRS. None of the following modifications in immunosuppression were associated with the development of IRS: any dose reduction (without discontinuation) of calcineurin inhibitor, >50% reduction of calcineurin inhibitor, discontinuation of prednisone, any reduction of prednisone, >50% reduction of prednisone, and discontinuation of azathioprine/mycophenolate mofetil (Table 3).
Table 3.
Immunosuppressants in Patients With and Without Immune Reconstitution Syndrome
| Factor | IRS (n = 13) | No IRS (n = 76) | Odds of IRS |
P Value | |
|---|---|---|---|---|---|
| OR (95% CI) | Comparator | ||||
| Baseline immunosuppression | |||||
| Any CNI | 92.13 (12/13) | 93.4% (71/76) | 0.85 (.09–7.88) | No CNI | .883 |
| Tacrolimus | 84.6% (11/13) | 88.2% (67/76) | 0.74 (.14–3.88) | No tacrolimus | .721 |
| Cyclosporine A | 7.7% (1/13) | 5.3% (4/76) | 1.5 (.15–14.6) | No CsA | .727 |
| Sirolimus | 7.7% (1/13) | 9.2% (7/76) | 0.82 (.09–7.29) | No sirolimus | .850 |
| Azathioprine | 0/13 | 4.0% (3/76) | 0.0 (0–7.82) | No azathioprine | .463 |
| Mycophenolate mofetil | 84.6% (11/13) | 65.3% (50/76) | 2.86 (.6–14.17) | No MMF | .184 |
| Prednisone, median dose, mg (IQR) | 5 (5–7.5) | 5 (5–10) | 0.90 (.75–1.07) | Continued | .237 |
| Triple therapy (CNI, MMF, prednisone) | 69.2% (9/13) | 52.6% (40/76) | 2.02 (.57–7.15) | No triple therapy | .273 |
| Anti–T-cell agent use | 0/13 | 4.0% (3/76) | Unable to calculatea | No T-cell agent use | .619 |
| Change in immunosuppression at diagnosis of cryptococcosisb | |||||
| Discontinuation of CNI | 50.0% (6/12) | 13.8% (9/65) | 6.88 (1.91–24.76) | Continue CNI | .008 |
| Time to stopping CNI from diagnosis, d | 5.3 (3.5–7) | 3.5 (3.5–7) | 0.94 (.75–1.19) | Continuous | .614 |
| Time to stopping CNI from antifungal therapy, d | 3.5 (1.5–7) | 2.8 (1.6–6.1) | 0.90 (.73–1.10) | Continuous | .305 |
| Time to IRS from stopping CNI, d | 20 (13–34) | … | … | … | … |
| Any reduction of CNI | 91.7% (11/12) | 85.1% (56/65) | 1.77 (.20–15.40) | No reduction | .606 |
| ≥50% reduction of CNI | 75.0% (9/12) | 63.5% (40/63) | 1.73 (.42–7.02) | <50% reduction | .446 |
| Discontinuation of prednisone | 8.3% (1/12) | 3.3% (2/62) | 2.73 (.23–32.7) | Continue | .429 |
| Any reduction of prednisone | 25.0% (3/12) | 19.4% (12/62) | 1.39 (.33–5.92) | No reduction | .856 |
| ≥50% reduction of prednisone | 8.3% (1/12) | 17.8% (11/62) | 0.49 (.06–4.4) | <50% reduction | .528 |
| Discontinuation of azathioprine/MMF | 54.6% (6/11) | 48.9% (23/47) | 1.25 (.33–4.67) | Continue azathioprine/MMF | .738 |
| Discontinuation of all agents | 1/13 | 0/75 | Unable to calculatea | Continue all agents | .146 |
Data are presented as % (No.) unless otherwise specified.
Abbreviations: CI, confidence interval; CNI, calcineurin-inhibitor agent; CsA, cyclosporine A; IQR, interquartile range; IRS, immune reconstitution syndrome; MMF, mycophenolate mofetil; OR, odds ratio.
a Unable to calculate due to zero in one of the values.
b One IRS patient and 5 non-IRS patients were not on CNI at diagnosis; 1 IRS and 15 non-IRS patients were not on prednisone; and 2 IRS and 16 non-IRS patients were not on azathioprine or MMF. The denominators reflect these numbers.
However, compared with SOT recipients without IRS, cases with IRS were significantly more likely to have CNS disease (84.6% [11/13] vs 40.0% [30/76]; P = .008), disseminated cryptococcosis at baseline (92.3% [12/13] vs 51.3% [39/76]; P = .022), and discontinuation of the calcineurin inhibitor (50% [6/12] vs 13.8 [9/65]; P = .008). Of the patients with cryptococcal disease limited to the lungs, only 2.9% developed IRS compared with 22.2% (P = .012) of those with extrapulmonary involvement (Table 2). Logistic regression analyses were performed to determine the variables that predicted risk of IRS. Disseminated and extrapulmonary disease correlated highly with CNS involvement (28/41 patients with CNS disease by definition had disseminated cryptococcosis, and all had extrapulmonary disease). Multivariate analyses therefore included CNS disease and discontinuation of calcineurin inhibitor in the model. CNS disease (adjusted OR, 6.23 [95% CI, 1.22–31.75]; P = .03) and discontinuation of calcineurin inhibitor (adjusted OR, 5.11 [95% CI, 1.33–19.69]; P = .02) were independently associated with IRS. IRS occurred in 2.6% (1/13) of patients with none of the aforementioned factors, 18.8% (6/32) with 1 factor, and 50% (6/12) of the patients with both factors present (χ2 for trend, P = .0001).
IRS in Patients With CNS Disease
Given that IRS developed in 26.8% (11/41) of the patients with CNS cryptococcosis, and 84.6% (11/13) of the patients with IRS had CNS disease, we assessed potential risk factors for IRS specifically in patients with CNS cryptococcosis. Compared with transplant recipients without CNS disease–associated IRS, CNS cases with IRS were more likely to have abnormal CNS imaging at baseline (81.8% [9/11] vs 40.0% [10/25]; P = .03) and to have calcineurin-inhibitor agent discontinued at the onset of disease (54.6% [6/11] vs 21.4% [6/28]; P = .051) (Table 4). None (0/11) of the cases without aforementioned factors, 35% (7/20) with 1 factor, and all patients (4/4) with both abnormal imaging and discontinuation of calcineurin-inhibitor agent (χ2 for trend, P = .0004) developed IRS.
Table 4.
Characteristics of Transplant Recipients With Central Nervous System Cryptococcosis Who Did and Those Who Did Not Have Immune Reconstitution Syndrome
| Factor | CNS Disease and IRS (n = 11) | CNS Disease and No IRS (n = 30) | Odds of IRS, OR (95% CI) | Comparison Group | P Value |
|---|---|---|---|---|---|
| Baseline characteristics of patients | |||||
| Age, y, median (IQR) | 56.5 (42–58) | 58.5 (52–63) | 0.97 (.91–1.03) | Continuous | .29 |
| Sex, female | 45.5% (5/11) | 30.0% (9/30) | 1.94 (.47–8.05) | Male | .28 |
| Type transplant | |||||
| Kidney | 36.4% (4/11) | 56.7% (17/30) | 0.4 (.11–1.82) | Not kidney | .21 |
| Liver | 27.3% (3/11) | 10.0% (3/30) | 3.37 (.57–20.1) | Not liver | .18 |
| Lung | 0/11 | 6.7% (2/30) | 0.0 (0–5.45) | Not lung | .38 |
| Heart | 9.1% (1/11) | 16.7% (5/30) | 0.50 (.05–4.83) | Not heart | .55 |
| Pancreas | 27.3% (3/11) | 10.0% (3/30) | 3.38 (.57–20.10) | Not pancreas | .18 |
| Retransplant | 27.3% (3/11) | 20.0% (6/30) | 1.50 (.30–7.43) | Not retransplant | .62 |
| Immunosuppression | |||||
| CNI (any) | 90.9% (10/11) | 90.0% (27/30) | 1.11 (.10–11.96) | No CNI | .93 |
| Tacrolimus | 81.8% (9/11) | 83.3% (25/30) | 0.90 (.15–5.49) | No tacrolimus | .91 |
| Renal failure | 27.3% (3/11) | 33.3% (10/30) | 0.75 (.16–3.46) | No renal failure | .71 |
| CMV infection | 18.2% (2/11) | 16.7% (5/30) | 1.11 (.18–6.78) | No CMV infect | .91 |
| CMV disease | 9.1% (1/11) | 3.3% (1/30) | 2.90 (.17–50.82) | No CMV disease | .47 |
| Characteristics of cryptococcal disease | |||||
| Onset of disease <1 y posttransplant | 63.6% (7/11) | 27.6% (8/29) | 4.59 (1.05–20.06) | Onset >1 y posttransplant | .043 |
| Fungemia | 36.4% (4/11) | 47.8% (11/23) | 0.62 (.14–2.73) | No fungemia | .53 |
| Serum antigen positive | 80.0% (8/10) | 89.7% (26/29) | 0.46 (.07–3.27) | Antigen negative | .44 |
| Serum antigen ≥1:64 | 62.5% (5/8) | 77.8% (21/27) | 0.48 (.09–2.59) | Serum antigen <1:64 | .39 |
| Pulmonary disease | 63.6% (7/11) | 40.0% (12/30) | 2.62 (.63–10.96) | No pulmonary disease | .19 |
| Cutaneous disease | 0/11 | 20.0% (6/30) | 0.0 (0–1.55) | No cutaneous disease | .11 |
| Abnormal CNS imaging at baseline | 81.8% (9/11) | 40.0% (10/25) | 6.75 (1.20–38.02) | Normal CNS imaging | .03 |
| CNS mass lesion | 54.6% (6/11) | 21.4% (6/28) | 4.4 (.99–19.54) | No mass lesion | .051 |
| CSF antigen positive | 90.9% (10/11) | 96.6% (28/29) | 0.36 (.02–6.26) | CSF antigen negative | .48 |
| CSF antigen titer, median (IQR) | 1:512 (1:2–1:4096) | 1:256 (1:8–1:1024) | 1.00 (1.00–1.00) | Continuous | 0.68 |
| CSF white cell count/µL | 24 (2–80) | 82 (15–181) | 1.31 (.35–4.97) | Continuous | .69 |
| CSF protein, mg/dL | 104 (36–162) | 74 (52–108) | 1.00 (.99–1.01) | Continuous | .45 |
| CSF culture positive | 60% (6/10) | 80.8% (21/26) | 0.36 (.07–1.76) | Negative culture | .21 |
| Opening pressure, cm water | 15.5 (4.5–28) | 22.2 (2.7–29) | 0.99 (.99–1.00) | Continuous | .74 |
| CSF antigen positive | 90.9% (10/11) | 96.6% (28/29) | 0.36 (.02–6.26) | CSF antigen negative | .48 |
| Management of immunosuppression at diagnosis of cryptococcosis | |||||
| CNI discontinued | 54.6% (6/11)20 (13–34) | 21.4% (6/28) | 4.40 (.99–19.54) | CNI continued | .051 |
| ≥50% CNI reduction | 81.8% (9/11) | 57.1% (16/28) | 3.38 (.61–18.57) | <50% reduction | .16 |
| Mycophenolate mofetil discontinued | 54.6% (6/11) | 50.0% (14/28) | 1.20 (.30–4.86) | Mycophenolate mofetil continued | .80 |
| Prednisone discontinued | 0/10 | 7.7% (2/26) | 0.0 (0–5.20) | Prednisone continued | .37 |
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CNI, calcineurin inhibitor agent; CNS, central nervous system; CSF, cerebrospinal fluid; IQR, interquartile range; IRS, immune reconstitution syndrome; OR, odds ratio.
Outcomes
Graft rejection after the diagnosis of cryptococcosis was documented in 15.4% (2/13) of patients with IRS vs 2.6% (2/76) in those without IRS (P = .07). Calcineurin inhibitor was discontinued within 1 week of diagnosis for 1 patient with IRS and rejection, and the other 3 patients with rejection episodes had 50%–75% reduction in CNI within 1 week of diagnosis; this was not significantly different from those not experiencing rejection (P = .289). The mortality rate was 13.5% (12/89) for the entire cohort; 15.3% (2/13) in patients with IRS; and 13.2% (10/76) in patients without IRS (P = .828). None of the deaths were attributable to IRS (Table 5).
Table 5.
Description of Solid Organ Transplant Recipients With Cryptococcosis-Associated Immune Reconstitution Syndrome
| Patient | Type of Transplant | Time to Onset of Diseasea | Presentation of Cryptococcosis |
Primary Antifungal Therapy | Interval to Onset of IRSb | Presentation of
IRS |
Management Following IRS | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sites | Basis of Diagnosis | Fungemia | Sites | Diagnostic Workup | |||||||
| 1 | Kidney | 26.5 | CNS, lung | Culture | Yes | Ambisome | 16 d | New pulmonary infiltrates | Bronchoscopy with encapsulated yeast forms but negative cultures | No change in antifungal therapy | Died 35 d post-IRS of cardiac cause |
| 2 | Liver | 6.9 | Cutaneous | Culture | No | AmBd + 5-FC | 28 d | New lung nodules, worsening skin nodules | Bronchoscopy and skin biopsy with encapsulated yeast forms but negative cultures | Fluconazole maintenance continued | Alive |
| 3 | Liver- kidney | 8.6 | CNS | Culture | Yes | AmBd | 63 d | New leptomeningeal enhancement | Leptomeningeal biopsy with encapsulated yeast forms but negative cultures | Fluconazole maintenance, discontinued, AmBd restarted and corticosteroids added | Alive |
| 4 | Kidney | 1.7 | CNS | CSF antigen | No | Abelcet + 5-FC | 45 d | New CNS lesion | CSF culture negative, CSF antigen decreased | Fluconazole maintenance, discontinued, Abelcet restarted | Alive |
| 5 | Pancreas | 62.0 | CNS, lung | CSF antigen | No | Abelcet | 89 d | New lung nodules and spinal arachnoiditis | CSF culture negative, antigen decreased | Fluconazole maintenance, discontinued, Abelcet restarted and corticosteroids added | Alive |
| 6 | Kidney | 2.4 | CNS, lung | Culture | Yes | Abelcet + 5-FC | 14 d | Worsening CNS mass | CSF culture negative | Abelcet continued | Died |
| 7 | Heart | 9.4 | CNS, lung | Culture | Yes | AmBd + 5-FC | 48 d | New CNS lesions | CSF culture negative | Fluconazole maintenance continued | Alive |
| 8 | Kidney- pancreas | 58.5 | CNS, lung | CSF antigen | No | Abelcet + 5-FC | 81 d | Increase in lung nodules, new CNS lesion | CSF culture and antigen negative | Fluconazole maintenance continued | Alive |
| 9 | Kidney | 10.6 | CNS | Culture | Not done | Fluconazole (changed to ambisome on day 7) | 26 d; 2nd episode 79 d | Meningitis New CNS lesion | CSF culture negative | Ambisome continued, corticosteroids added 2nd episode; continued on fluconazole, corticosteroids added | Died 1 y post-IRS, No autopsy |
| 10 | Liver | 6.3 | CNS | Culture | Yes | Ambisome + 5 FC | 112 d | New lepto-meningeal enhancement | CSF culture negative (was positive at baseline) | Fluconazole maintenance, discontinued, Abelcet restarted and corticosteroids added | Alive |
| 11 | Kidney- pancreas | 20.3 | CNS, lung | Culture | No | Ambisome + 5 FC | 13 d | New CNS lesion | CSF culture negative (was positive at baseline) | Ambisome continued and corticosteroids added | Alive |
| 12 | Liver | 7.3 | CNS, lung | Culture | No | Fluconazole | 98 d | New pulmonary lesions, pleural effusion | Pleural fluid culture negative (was positive at baseline) | Fluconazole maintenance, continued | Alive |
| 13 | Heart | 17.0 | Lung, cutaneous | Culture | Yes | Ambisome | 116 d | New skin and osteoarticular lesions | Tissue cultures negative (were positive at baseline) | Surgery, fluconazole maintenance continued | Alive |
Abbreviations: 5-FC, 5-flucytosine; AmBd, amphotericin B deoxycholate; CNS, central nervous system; CSF, cerebrospinal fluid; IRS, immune reconstitution syndrome.
a Data represent time to onset of cryptococcosis after transplant (months).
b Data represent time to onset of IRS (days) after antifungal therapy.
DISCUSSION
Observations in this study have clinically relevant implications for the management of SOT recipients with cryptococcosis. IRS developed in 14% of the transplant recipients with cryptococcosis. IRS has been observed as case reports and in 5%–11% of transplant recipients in previous case series, typically between 4 and 6 weeks after antifungal therapy [17, 18, 21]. Prior studies, however, were not specifically designed to assess IRS. To our knowledge, the current study is the first in-depth assessment of the characteristics, risk factors (including the impact of changes in immunosuppression), and outcomes using previously proposed criteria for IRS in SOT recipients.
Meningitis is the most common manifestation of CNS cryptococcosis. It is commonly associated with infection of the subarachnoid space and involvement of the underlying parenchyma to a variable extent [22]. Overt neuroimaging abnormalities such as CNS mass lesions, leptomeningitis, or hydrocephalus have been documented in 11%–25% of cases with cryptococcal CNS disease [2, 22]. Such lesions occurred in 29% of the SOT recipients with cryptococcosis in a previous study [22]. Whereas most neuroimaging abnormalities were present at baseline, approximately 20% of the lesions developed after the initiation of antifungal therapy and these were attributed to IRS [22]. Outcome varied depending on the type of lesions. Mortality was 50% in patients with CNS mass lesions; those with leptomeningitis (despite higher CSF cryptococcal antigen titers) had lower mortality (12.5%) [22].
In our study, patients with CNS disease or disseminated cryptococcosis were significantly more likely to develop IRS. Conversely, those with disease limited to the lungs were less likely to have IRS. Disseminated disease is indicative of greater severity of disease or organism burden and conferred a higher risk of IRS in other hosts and SOT recipients with opportunistic infections, including cryptococcosis [21, 23]. Among patients with CNS disease in our study, those with neuroimaging abnormalities, particularly mass lesions, were more likely to develop IRS, irrespective of serum or CSF cryptococcal antigen titers and fungemia. These data suggest that host immune response is a significant contributor to pathogenesis and disease expression. Along these lines, a previous study has also suggested that host immune function is a key determinant of morbidity and outcomes in patients with CNS cryptococcosis [24].
A major challenge confronting the transplant clinician is the management of immunosuppression in transplant recipients diagnosed with cryptococcosis. Reduction or even the discontinuation of immunosuppressive drug therapies, whenever possible, appears to be intuitively logical in transplant recipients with serious infections. Expert opinion and guidelines of the Infectious Diseases Society of America and the American Society of Transplantation recommend reduction in immunosuppression, with consideration of initially lowering the corticosteroid dose [25, 26]. However, no formal studies or evidence-based data correlating the risk of IRS with modification in immunosuppression exist. Our study shows that discontinuation of calcineurin inhibitors was the only modification of immunosuppression that influenced the development of IRS. Patients in whom the calcineurin inhibitor was discontinued had a 5-fold higher risk of IRS. Neither discontinuation nor reduction of other agents affected this risk. The biologic basis of these observations may be the selective effect of specific immunosuppressive agents on immune function with greater suppression of Th1 and Th17 with calcineurin inhibitors compared with other components of the immunosuppressive regimen [27]. Given that calcineurin inhibitors have synergistic interactions with antifungal agents, continuation at reduced dosages as opposed to stopping these agents appears rational [28].
Although not statistically significant, patients with IRS had a 7-fold higher risk of allograft rejection than those without IRS. Similar observations have also been reported in a previous study [29]. It is plausible that the immune milieu in patients with IRS is also conducive to inflammatory pathology that underlies allograft injury. Reduction or discontinuation of calcineurin inhibitors could also have been a contributory factor. The precise basis of these observations needs to be determined, however.
Several limitations of this study deserve to be acknowledged. Reliable diagnostic criteria or laboratory assays that can unequivocally diagnose IRS do not exist, and there are no markers for IRS specifically in SOT recipients. In our patients, this entity occurred in the setting of microbiologic response and there was no documented evidence of disease progression or alternative etiologies to account for the presentation. Nevertheless, it is plausible that some cases may have been misdiagnosed or had disease progression. Indeed, experts believe that IRS and microbiologic disease progression can appear simultaneously [25] and that these phenomena may not be mutually exclusive. It is also possible that patients with baseline imaging abnormalities may have been more likely to have follow-up studies performed. In addition, the study was based on data generated by routine clinical care, and protocol imaging studies were not performed. Finally, formal assessments of the net state of immunosuppression with immunologic assays that measure the degree of immune impairment were not done. Strengths of our study include systematic collection of data using a uniform data collection tool and the fact that this was a multicenter study, which renders our findings generalizable.
IRS is a clinical entity that is gaining recognition as a significant complication in transplant recipients with cryptococcosis. We have determined factors that can be used to identify patients at risk for this entity and have discussed the potential biologic plausibility for their association with IRS. Most importantly, we have shown that the manner by which the immunosuppression is modified may independently influence the risk of IRS. Future studies are warranted to further delineate this entity and define its biologic basis.
Note
Potential conflicts of interest. The following authors have received research funding through their institutions: B. D. A. has received support from Pfizer, Astellas, Charles River Laboratories, Synexis, and Viamet; G. M. L. has received support from Astellas, Qiagen, and T2 Biotechnologies; N. S. has received investigator-initiated grant support from Pfizer. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
- 1.Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7:375–81. doi: 10.3201/eid0703.010302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation. 1996;61:146–67. doi: 10.1097/00007890-199601150-00027. [DOI] [PubMed] [Google Scholar]
- 3.Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Hematol Oncol Clin North Am. 2011;25:193–213. doi: 10.1016/j.hoc.2010.11.013. [DOI] [PubMed] [Google Scholar]
- 4.Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 1989;3:77–102. [PubMed] [Google Scholar]
- 5.John GT, Mathew M, Snehaltha E, et al. Cryptococcosis in renal allograft recipients. Transplantation. 1994;58:855–6. [PubMed] [Google Scholar]
- 6.Blanche P, Gombert B, Ginsburg C, et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis. 1998;30:615–6. doi: 10.1080/00365549850161223. [DOI] [PubMed] [Google Scholar]
- 7.Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol. 2003;1:17–24. doi: 10.1038/nrmicro732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol. 1998;36:12–25. [PubMed] [Google Scholar]
- 9.Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun. 1995;63:1725–31. doi: 10.1128/iai.63.5.1725-1731.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun. 1996;64:2846–9. doi: 10.1128/iai.64.7.2846-2849.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Decken K, Kohler G, Palmer-Lehmann K, et al. Interleukin-12 is essential for protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun. 1998;66:4994–5000. doi: 10.1128/iai.66.10.4994-5000.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Chaka W, Hyderman R, Gangaidzo I, et al. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin-8 levels. J Infect Dis. 1997;176:1633–6. doi: 10.1086/517344. [DOI] [PubMed] [Google Scholar]
- 13.Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis. 2004;57:137–45. [PubMed] [Google Scholar]
- 14.Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV seronegative woman. Clin Infect Dis. 2004;39:e78–82. doi: 10.1086/424746. [DOI] [PubMed] [Google Scholar]
- 15.Massarollo PC, Mies S, Abdala E, Leitao RMRS. Immunosuppression withdrawal for treatment of severe infections in liver transplantation. Transplant Proceed. 1998;4:1472–4. doi: 10.1016/s0041-1345(98)00321-2. [DOI] [PubMed] [Google Scholar]
- 16.Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007;7:395–401. doi: 10.1016/S1473-3099(07)70085-3. [DOI] [PubMed] [Google Scholar]
- 17.Crespo G, Cervera C, Michelena J, Marco F, Moreno A, Navasa M. Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient. Liver Transpl. 2008;14:1671–4. doi: 10.1002/lt.21601. [DOI] [PubMed] [Google Scholar]
- 18.Lanternier F, Chandesris MO, Poire S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant. 2007;12:2826–8. doi: 10.1111/j.1600-6143.2007.01994.x. [DOI] [PubMed] [Google Scholar]
- 19.De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. doi: 10.1086/588660. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195:756–64. doi: 10.1086/511438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Singh N, Lortholary O, Alexander BD, et al. An “immune reconstitution syndrome”-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis. 2005;40:1756–61. doi: 10.1086/430606. [DOI] [PubMed] [Google Scholar]
- 22.Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation. 2008;56:647–51. doi: 10.1097/TP.0b013e3181814e76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043–9. doi: 10.1097/01.aids.0000174450.70874.30. [DOI] [PubMed] [Google Scholar]
- 24.Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect. 2010;61:419–26. doi: 10.1016/j.jinf.2010.08.004. [DOI] [PubMed] [Google Scholar]
- 25.Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322. doi: 10.1086/649858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Baddley JW, Forrest GN AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):242–9. doi: 10.1111/ajt.12116. [DOI] [PubMed] [Google Scholar]
- 27.Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis. 2011;53:168–76. doi: 10.1093/cid/cir276. [DOI] [PubMed] [Google Scholar]
- 28.Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother. 2008;52:735–8. doi: 10.1128/AAC.00990-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with C. neoformans associated immune reconstitution syndrome. Transplantation. 2005;80:1131–3. doi: 10.1097/01.tp.0000180530.17683.02. [DOI] [PubMed] [Google Scholar]